Literature DB >> 28493050

Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.

Amal Hofni1, Basim A Shehata Messiha2, Safwat A Mangoura3.   

Abstract

Endothelial dysfunction is a major contributor to the pathogenesis of vascular disease in diabetes mellitus and RhoA/Rho-kinase (ROCK) system appears to play a crucial role in this setting. The present study was conducted to investigate the effect of the selective ROCK inhibitor, fasudil, on diabetes-related endothelial dysfunction and elucidated its underlying mechanism(s). Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 50 mg/kg), and fasudil (5 mg/kg per day) was orally administered for 8 weeks. Our results showed that fasudil administration attenuated the increased activity/expression of ROCK (627.5 ± 27 vs. 247.8 ± 19.1) and the NADPH oxidase subunits, NOX2 and p47phox, in diabetic rat aorta. Fasudil could reduce the elevated tumor necrosis factor (TNF)-α (70.2 ± 14.1 vs. 25.3 ± 5.2) and transforming growth factor (TGF-β) levels and restored the deficit in antioxidant level of the diabetic aorta. Additionally, fasudil markedly improved the endothelial dysfunction in the diabetic aorta (73.8 ± 8.1 vs. 47.42 ± 8.69) and corrected the dysregulated endothelial nitric oxide (eNOS) expression. In conclusion, the present study demonstrates that fasudil effectively ameliorates the endothelial dysfunction in STZ-induced diabetic rats through inhibition of the Rho/ROCK pathway and thereby reducing the TNF-α-mediated NADPH oxidase activation.

Entities:  

Keywords:  Diabetes-oxidative stress; Endothelial dysfunction; Fasudil; RhoA kinase; Streptozotocin

Mesh:

Substances:

Year:  2017        PMID: 28493050     DOI: 10.1007/s00210-017-1379-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  51 in total

1.  Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases.

Authors:  S Montaner; R Perona; L Saniger; J C Lacal
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

2.  Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.

Authors:  Amal Hofni; Mohamed A El-Moselhy; Ashraf Taye; Mohamed M Khalifa
Journal:  Eur J Pharmacol       Date:  2014-10-27       Impact factor: 4.432

3.  A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

Authors:  Yuichi Kikuchi; Muneharu Yamada; Toshihiko Imakiire; Taketoshi Kushiyama; Keishi Higashi; Naomi Hyodo; Kojiro Yamamoto; Takashi Oda; Shigenobu Suzuki; Soichiro Miura
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

4.  Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway.

Authors:  Steffen-Sebastian Bolz; Lukas Vogel; Daniel Sollinger; Roland Derwand; Cor de Wit; Gervaise Loirand; Ulrich Pohl
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

5.  Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to glycation, oxidative stress and cytokine production in stz diabetic rats.

Authors:  Mohamed M El-seweidy; Sahar E El-Swefy; Rawia S Ameen; Reem M Hashem
Journal:  Pharmacol Res       Date:  2002-05       Impact factor: 7.658

6.  How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

Authors:  Adelle Dawson; Bushra S Rana; Stuart D Pringle; Louise A Donnelly; Andrew D Morris; Allan D Struthers
Journal:  J Hypertens       Date:  2004-07       Impact factor: 4.844

7.  Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.

Authors:  Masao Takemoto; Jianxin Sun; Junko Hiroki; Hiroaki Shimokawa; James K Liao
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

Review 8.  Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.

Authors:  Ram Kumar Mishra; Reshma Alokam; Dharmarajan Sriram; Perumal Yogeeswari
Journal:  Curr Diabetes Rev       Date:  2013-05

Review 9.  Reactive oxygen species in the vasculature: molecular and cellular mechanisms.

Authors:  Yoshihiro Taniyama; Kathy K Griendling
Journal:  Hypertension       Date:  2003-10-27       Impact factor: 10.190

10.  The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes.

Authors:  Andrea O Ciobanu; Carmen Lucia Gherghinescu; Raluca Dulgheru; Stefania Magda; Ruxandra Dragoi Galrinho; Maria Florescu; Suzana Guberna; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2013-06
View more
  2 in total

1.  Berberine elevates mitochondrial membrane potential and decreases reactive oxygen species by inhibiting the Rho/ROCK pathway in rats with diabetic encephalopathy.

Authors:  Lin Tian; Hong Ri; Jiping Qi; Peng Fu
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

2.  Sevoflurane and isoflurane inhibit KCl-induced, Rho kinase-mediated, and PI3K-participated vasoconstriction in aged diabetic rat aortas.

Authors:  Shaozhong Yang; Yu Liu; Shanshan Huang; Feihong Jin; Feng Qi
Journal:  BMC Anesthesiol       Date:  2021-09-01       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.